Komrokji, Rami S. http://orcid.org/0000-0002-1876-5269
Platzbecker, Uwe http://orcid.org/0000-0003-1863-3239
Fenaux, Pierre
Zeidan, Amer M.
Garcia-Manero, Guillermo http://orcid.org/0000-0002-3631-2482
Mufti, Ghulam J.
Santini, Valeria http://orcid.org/0000-0002-5439-2172
Díez-Campelo, María http://orcid.org/0000-0002-1467-6779
Finelli, Carlo http://orcid.org/0000-0001-9372-1197
Jurcic, Joseph G.
Greenberg, Peter L.
Sekeres, Mikkael A. http://orcid.org/0000-0003-2009-6524
DeZern, Amy E.
Savona, Michael R. http://orcid.org/0000-0003-3763-5504
Shetty, Jeevan K.
Ito, Rodrigo
Zhang, George
Ha, Xianwei
Backstrom, Jay T.
Verma, Amit
Article History
Received: 30 March 2021
Revised: 6 January 2022
Accepted: 1 February 2022
First Online: 26 February 2022
Competing interests
: RSK: Advisory board fees from AbbVie, Acceleron, BMS, Geron, Jazz Pharmaceuticals, and Novartis; speakers’ bureau fees from BMS and Jazz Pharmaceuticals. UP: Grant support from Amgen, Janssen Biotech, Merck and Novartis; grant and travel support, and lecture, steering committee, and consulting fees, travel support from Celgene/BMS; and lecture fees from Novartis. PF: Consulting fees from Celgene. AMZ: Grant support, honoraria, clinical trial committee and consulting fees, from AbbVie, Celgene/BMS, and Novartis; consulting fees and honoraria from Acceleron, Agios, Astellas. Beyondspring, Cardinal Health, Daiichi Sankyo, Janssen, Jazz Pharmaceuticals, Seattle Genetics, Syndax, Taiho, and Tyme; grant support from ADC Therapeutics, Astex and Medimmune/ AstraZeneca; grant support, consulting fees and honoraria from Amgen, Aprea, Boehringer-Ingelheim, Cardiff Oncology, Incyte, Otsuka, Pfizer, Takeda, and Trovagene; honoraria, consulting and clinical trial committee fees from Gilead and Kura; clinical trial committee fees from Geron. GG-M: Grant support and consulting fees from Astex Pharmaceuticals, BMS, Genentech, and Helsinn Healthcare; grant support from AbbVie, Amphivena Therapeutics, Aprea, Curis, Celgene, Forty Seven, H3 Biomedicine, Janssen, Merck, Novartis, and Onconova Therapeutics. GJM: Grant support from Celgene/BMS and Novartis. VS: Advisory board and lecture fees from Celgene/BMS; travel support from Janssen Biotech; advisory board fees from Geron, Gilead, Menarini, Novartis, and Takeda Oncology; grant support from Celgene. MD-C: Consulting fees from Celgene/BMS, Novartis, and Takeda. CF: Grant support, advisory committees, and speaker fees from Celgene/BMS; advisory committee and speaker fees from Novartis; consultancy from Takeda; advisory board fees from Janssen Pharmaceuticals. JGJ: Grant and travel support, and advisory board fees, AbbVie; grant support from Arog Pharmaceuticals, Astellas Pharma, Forma Therapeutics, Genentech USA, Gilead Sciences, PTC Therapeutics, and Syros Pharmaceuticals; advisory board fees from AstraZeneca; grant support, advisory board fees, and travel support from BMS/Celgene; grant support and consulting fees from Daiichi Sankyo; end-point committee fees from Novartis. PLG: Grant support from Celgene. MAS: Advisory boards for BMS, Gilead, Novartis, and Pfizer. AED: No competing financial interests. MRS: Steering committee and data and safety monitoring board fees from Celgene; consultancy and advisory for CTI, Geron, Karyopharm, Novartis, Ryvu, Taiho, Takeda, and TG Therapeutics; grant support from Astex, Incyte, Takeda, and TG Therapeutics; and equity in Karyopharm. JKS: Current employment at and equity in BMS. RI: Former employment and current equity in BMS; current employment and equity in Eli Lilly and Company. GZ and XH: Current employment at BMS. JTB: equity in BMS; current employment and equity in Acceleron Pharma. AV: Equity in Stelexis; consultancy and grant support from BMS; consultancy and honoraria from Acceleron Pharma; grant support from Janssen and Medpacto.